Latandrops (Latanoprost)

Latanoprost activates prostaglandin F (FP) receptors in the eye, which remodels the extracellular matrix of the ciliary muscle. This remodeling increases the uveoscleral outflow of aqueous humor, thereby decreasing intra‑ocular pressure and providing therapeutic benefit in glaucoma.

The dosing regimen for Latandrops is determined by the prescribing clinician. Typically, one drop is instilled in the affected eye(s) once daily in the evening, but the exact dose and timing should follow the prescriber’s instructions.

Safety data for latanoprost in pregnancy and lactation are limited, and the product carries an unknown pregnancy category. Healthcare providers should weigh potential benefits against risks before prescribing to pregnant or nursing individuals.

To request Latandrops, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details and any necessary import documentation.

Latandrops (latanoprost) belongs to the prostaglandin analog class, which generally offers once‑daily dosing and strong IOP‑lowering efficacy. Compared with beta‑blockers like timolol, prostaglandin analogs often have a more favorable dosing schedule and may be better tolerated, though individual response varies.

Latandrops should be stored at ambient temperature, below 25 °C, in its original container. Protect the bottle from light and moisture, and keep it out of reach of children. Do not freeze the solution.

Instill one drop of Latandrops into the affected eye(s) once daily, preferably in the evening. Tilt the head back, pull down the lower eyelid to create a pocket, and avoid touching the tip of the bottle to the eye or any surface to maintain sterility.

Serious adverse events, though rare, include severe allergic reactions, uveitis or iritis, corneal edema, and a paradoxical rise in intra‑ocular pressure. Patients should seek immediate medical attention if they experience significant eye pain, vision changes, or signs of an allergic response.

Latandrops is contraindicated in individuals with known hypersensitivity to latanoprost or any excipients in the formulation. Caution is advised for patients with active ocular inflammation, recent ocular surgery, or those using other prostaglandin analog eye drops.